Cancer may occur at earlier ages in later generations of families with Lynch syndrome

Questions To Ask Your Health Care Provider

• I have an MLH1 mutation. When should I begin cancer screening?
• My family has a known MLH1 mutation. When should cancer screening start for future generations?
• I have a mutation in an LS gene other than MLH1. Given my family history, when should I begin cancer screening?
• What cancer screening tests do you recommend?

Open Clinical Trials

The following screening and prevention studies are open to people with Lynch syndrome. 

Colorectal cancer

• NCT05410977: Collecting Blood and Stool Samples to Detect Colorectal Cancer or Precancerous Polyps in Lynch Syndrome Patients, CORAL Study. This study will determine the effectiveness of a screening technique, multitarget stool DNA testing, for the detection of colorectal cancer in individuals with Lynch syndrome. 
• NCT05396846: My Best GI Eating Study. This study will test three different diets in people who are overweight and who have an increased risk of colorectal cancer. The study will look at whether these diets improve eating and possibly lead to weight loss.
• NCT05411718: Studying the Use of Naproxen and Aspirin for Cancer Prevention in People with Lynch Syndrome. The study will measure  the effect of naproxen or aspirin on the immune cells in the gastrointestinal tract of people with Lynch syndrome. The trial will also evaluate any symptoms from the medications and any other changes of the colon and rectum.

• NCT06708429: Lynch Syndrome X-Talk of Enteral Mucosa With Immune System (LYNX-EYE). This study will collect samples from blood, the lining of the intestinal tract, mucosal-based, and hair to look at the connection between the immune system and cancer risk in people with Lynch Syndrome.  

Gynecologic cancers

• Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE). The goal of this effort is to develop a clinical diagnostic test to detect early-onset ovarian cancer, as currently, no reliable screening or early-detection tests are available.

Prostate cancer

• NCT03805919: Men at High Genetic Risk for Prostate Cancer. This is a prostate cancer screening study using MRI in high-risk men is open to men with Lynch syndrome and other mutations.
• NCT05129605: Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS).  This study looks at how well prostate MRI works as a screening tool for men at high risk for prostate cancer. Enrollment is open to men with an inherited mutation in ATM, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53 and other genes. 

Pancreatic cancer

• NCT03568630: Blood Markers of Early Pancreas Cancer. This pancreatic cancer study involves blood samples taken over time to identify biomarkers of pancreatic cancer in high-risk people. Enrollment is open to people with certain mutations linked to increased cancer risk.
• NCT03250078: A Pancreatic Cancer Screening Study in Hereditary High-Risk Individuals. The main goal of this study is to screen and detect pancreatic cancer and precursor lesions in individuals with a strong family history or genetic predisposition to pancreatic cancer. MRI and magnetic cholangiopancreatography (MRI/MRCP) will be utilized to screen for early-stage pancreatic lesions.